JP Morgan Chase
KBIO

JP Morgan Chase’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

JP Morgan Chase’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-211,532
Closed -$4.59M – 3778
2014
Q1 		$4.59M Buy
211,532
+20,451
+11% +$593K ﹤0.01% 2130
2013
Q4 		$6.76M Buy
191,081
+28,912
+18% +$969K ﹤0.01% 1987
2013
Q3 		$5.86M Buy
+162,169
New +$7.39M ﹤0.01% 2084

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

JP Morgan Chase's KBIO Position: Q2 2014 in Review

JP Morgan Chase sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q2 2014, closing a stake of 211,532 shares — an estimated $4.59M sold.

JP Morgan Chase first reported a position in KBIO in Q3 2013 and held it in 3 quarters. The position peaked at $6.76M in Q4 2013. 43 funds tracked by Wall St. Rank hold KBIO as of Q2 2014.

  • JP Morgan Chase reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q2 2014 after selling out during the quarter.
  • JP Morgan Chase sold 211,532 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q2 2014, an estimated $4.59M.
  • JP Morgan Chase first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q3 2013 and held it in 3 quarters.
  • JP Morgan Chase's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $6.76M in Q4 2013.
  • 43 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q2 2014.

Based on JP Morgan Chase's 13F filing for Q2 2014, filed 14 Aug 2014.